论文部分内容阅读
作者采用VAD或大剂量地塞米松治疗10例耐药性多发性骨髓瘤(MM),其中7例系VAD,3例系大剂量地塞米松冲击治疗,9例曾接受过烷化剂治疗,1例为耐药性高钙血症需住院治疗;3例对初期化疗产生抗药性:6例对初期化疗有效。 VAD方案包括长春新硷(0.4mg/日)和阿霉素(9mg/m~2/日),静脉输注,第1-4天,地塞米松40mg每晨1次,4天,分别于治疗周(?)的第1-4天,9-12天和17-20天,每个疗程21天,大剂量地塞米松为口服4天单药冲击治疗。所有患者均同时接受西米替丁抗酸治疗以及复方新诺明预防感染,2例在治疗早期死亡,分别于治后11天、10天死于假单胞菌属败血症和耐药性高钙血症及支气管肺炎,其余8例中,5例应用VAD化疗,3例应用地塞米松,7例初步疗效良好,5例(3例VAD,2例
The authors used VAD or high-dose dexamethasone in 10 patients with multi-drug resistant myeloma (MM), of which 7 were VAD, 3 were treated with high-dose dexamethasone, 9 were previously treated with alkylating agents, One case was resistant to hypercalcaemia requiring hospitalization; three cases were resistant to initial chemotherapy: 6 cases were effective for initial chemotherapy. The VAD regimen included vincristine (0.4 mg / day) and doxorubicin (9 mg / m 2 / day), intravenous infusion, day 1-4, dexamethasone 40 mg once daily for 4 days, Days 1-4, 9-12, and 17-20 days of treatment week (?), 21 days per course, and high-dose dexamethasone is a 4-day oral single-dose shock treatment. All patients received cimetidine antacid therapy and cotrimoxazole prophylaxis at the same time. Two patients died early in treatment. They died of Pseudomonas sepsis and drug-resistant sepsis 10 days after treatment on day 10 and 10 days respectively Serum and bronchopneumonia, the remaining 8 cases, 5 cases of VAD chemotherapy, 3 cases of dexamethasone, 7 cases of good initial effect, 5 cases (3 cases of VAD, 2 cases